THE LIVER FUNCTION TEST (TRANSAMINASE ENZYMES AND BILIRUBIN) AND THE KIDNEY FUNCTION TESTS (UREA, CREATININE) ANALYSIS IN MDR-TB DURING TREATMENT

Widaninggar Rahma Putri (Universitas Aisyiyah Yogyakarta)
Havida Widyastuti (Universitas Aisyiyah Yogyakarta)
Dhini Intan Cahyani (Universitas Aisyiyah Yogyakarta)
Wa Ode Hikma Fajar (Universitas Aisyiyah Yogyakarta)

Indonesian Journal of Health Sciences Research and Development (IJHSRD)
Vol. 8 No. 1 (2026): INDONESIAN JOURNAL OF HEALTH SCIENCES RESEARCH AND DEVELOPMENT

Background: Multi Drug Resistance Tuberculosis (MDR-TB) treatment caused side effects such as hepatotoxicity and acute kidney injury (AKI).  Monitoring liver and kidney function in patients during treatment is crucial to prevent complication. Methods: A retrospective study of 19 patients confirmed MDR-TB in the period 2022-2025. Liver function test (transaminase enzymes and bilirubin) and kidney function test (urea and creatinine) during the first three month of treatment were analyzed. Results: Statistically, there was no difference in all parameters (p>0.05). Increases in total bilirubin, SGOT, SGPT levels occurred in the third month of TB treatment. While urea and creatinine levels increased in the second and third months. Conclusion: Monitoring of liver and kidney function during MDR-TB treatment is necessary to monitor patient condition.